These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17374619)

  • 1. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma.
    Barakat RK; Singh N; Lal R; Verani RR; Finkel KW; Foringer JR
    Ann Pharmacother; 2007 Apr; 41(4):707-10. PubMed ID: 17374619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
    Lomax AJ; Hill PA; Ashley DM
    J Oncol Pharm Pract; 2013 Dec; 19(4):365-8. PubMed ID: 23235917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute interstitial nephritis associated with coadministration of vancomycin and ceftriaxone: case series and review of the literature.
    Plakogiannis R; Nogid A
    Pharmacotherapy; 2007 Oct; 27(10):1456-61. PubMed ID: 17896901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute interstitial nephritis due to cefoperazone.
    Torun D; Sezer S; Kayaselcuk F; Zumrutdal A; Ozdemir FN; Haberal M
    Ann Pharmacother; 2004 Sep; 38(9):1446-8. PubMed ID: 15213314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged renal failure secondary to antithymocyte globulin treatment in severe aplastic anemia.
    Barakat RK; Schmolck JP; Finkel KW; Foringer JR
    Ann Pharmacother; 2007 May; 41(5):895-8. PubMed ID: 17426071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.
    Saif MW; Longo WL; Israel G
    Clin Colorectal Cancer; 2008 Mar; 7(2):144-8. PubMed ID: 18501075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
    August DA; Serrano D; Poplin E
    J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
    Heinzerling JH; Huerta S
    Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal perforation due to bevacizumab in colorectal cancer.
    Saif MW; Elfiky A; Salem RR
    Ann Surg Oncol; 2007 Jun; 14(6):1860-9. PubMed ID: 17356952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
    Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H
    J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab-related surgical site complication despite primary tumor resection in colorectal cancer patients.
    Bège T; Lelong B; Viret F; Turrini O; Guiramand J; Topart D; Moureau-Zabotto L; Giovannini M; Gonçalves A; Delpero JR
    Ann Surg Oncol; 2009 Apr; 16(4):856-60. PubMed ID: 19156464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic interstitial nephritis in an 18-year-old due to intake of a compound analgesic].
    Jochum E; Janssen U
    Med Klin (Munich); 2006 Oct; 101(10):830-4. PubMed ID: 17039326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
    Krämer I; Lipp HP
    J Clin Pharm Ther; 2007 Feb; 32(1):1-14. PubMed ID: 17286784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic rectal cancer responding to third-line therapy employing bevacizumab after failure of oxaliplatin and irinotecan: case report.
    Shitara K; Munakata M; Muto O; Sakata Y
    Jpn J Clin Oncol; 2008 Jul; 38(7):493-6. PubMed ID: 18567598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab: current updates in treatment.
    Van Meter ME; Kim ES
    Curr Opin Oncol; 2010 Nov; 22(6):586-91. PubMed ID: 20811277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient and safe application of a FOLFIRI/bevacizumab combination to a patient with locally advanced rectal cancer and severe chronic renal failure.
    Cicin I; Karagol H; Uzunoglu S; Uygun K
    Onkologie; 2007 Feb; 30(1-2):65. PubMed ID: 17264528
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature.
    Yahata M; Nakaya I; Sakuma T; Sato H; Aoki S; Soma J
    BMC Res Notes; 2013 Nov; 6():450. PubMed ID: 24207130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report of perforation of an ileal neobladder after treatment of rectal cancer with bevacizumab and comment on mechanisms of intestinal perforation associated with bevacizumab.
    Liu SV; Gollard R; Iqbal S
    J Clin Pharm Ther; 2012 Oct; 37(5):607-9. PubMed ID: 22432770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.